Fig. 7.

Collection of phenotyping results on mammalian cells from literature. See Sections 4.4 for further details. (A) i – Measurements of transit time vs signal amplitude for normal and diabetic lymphocytes; ii – comparison of transit time (left) and signal amplitude (right) between normal and diabetic lymphocytes, where significant differences were observed (****p < 0.0001). (B) Measurements of impedance magnitude at 300 kHz vs opacity (impedance magnitude at 1.7 MHz / 300 kHz) for various cell populations; ii - Measurements of impedance magnitude at 300 kHz vs opacity (impedance magnitude at 1.7 MHz / 300 kHz) for untreated, TNF-α and LPS treated monocytes. (C) Measurements of electrical size vs opacity (impedance magnitude at 1.7 MHz / 300 kHz) for: i – neutrophils undergoing NETosis at different time points; ii – neutrophils undergoing NETosis induced via Cal and PMA. (D) Measurements of in-phase vs out-of-phase signals at 6 MHz (i) and 14 MHz (ii) for CD69⁺ and CD69⁻ T-lymphocytes (i) and unstimulated CD8⁺, CD69⁺ and CD69⁻ T-lymphocytes (ii). (E) i – Measurements of electrical size vs opacity (impedance magnitude at 2 MHz / 500 kHz) for CD146⁺ and CD146⁻ hBMMNCs; and distributions of electrical size (ii) and opacity (ii) for SSCs along passage number for one individual patient. (F) i – Distribution of signal amplitude at 450 kHz for a population of live an dead iBMDM cells; ii – comparison between viability estimations by flow cytometry (FCM) and impedance cytometry (HSIFC); iii – comparison between viability estimations by FCM and HSIFC for various cell types and treatments. Images were adapted with permission from (A) ref. ¹⁴⁵, copyright 2019 IOP Publishing, (B) ref. ⁶⁰, copyright 2018 Elsevier B.V., (C) ref. ⁶³ copyright 2019 The Royal Society of Chemistry, (D) ref. ⁷⁹, copyright 2017 Elsevier B.V., (E) ref. ¹⁶¹, copyright 2017 The Royal Society, (F) ref. ¹¹⁹, copyright 2020 Elsevier B.V..